Another oral non-peptide GLP-1 reported up to 11.3 per cent weight loss in phase 2
Results from the ACCESS phase 2b trial of aleniglipron, an oral small-molecule GLP-1, were published in Nature Medicine. In 230 adults with obesity or overweight, placebo-adjusted weight reduction at 36 weeks was 8.2, 9.8 and 11.3 per cent across three dose levels. The authors reported no apparent plateau in weight loss by the end of the double-blind period, with further reduction seen at an interim analysis of the open-label extension.
What this actually means
Phase 2 means this is a promising early signal, not a finished drug. It is years from a UK pharmacy, if it gets there at all, and plenty of phase 2 successes fail in phase 3.
The reason it is worth recording is the pattern. This is the third oral small-molecule GLP-1 to report solid results, after orforglipron's approval in the US and a separate phase 2 for a compound called CX11. Small molecules can be swallowed and mass-produced in a way that injectable peptides cannot, which is the actual bottleneck on access worldwide.
So the useful read is not that a new wonder drug is coming. It is that the supply and cost picture for this whole class looks different in five years than it does now.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.